Boehringer Ingelheim India Welcomes GST Council's Tax Reforms for the Healthcare Sector
GST
Dated:- 19-9-2025
PTI
Mumbai, Maharashtra, India – Business Wire India Boehringer Ingelheim India commends the recent measures announced by the GST Council aimed at reducing tax rates on medicines and life-saving drugs used for treatment of severe chronic diseases, cancer, rare diseases, medical apparatus, devices, diagnostic kits, and equipment. Additionally, exemption of GST on individual health insurance policies will make it affordable for the common man and drive insurance coverage in the country. The company believes that these reforms by the Government of India will strongly contribute to public health, access to innovative medicin
= = = = = = = =
Plain text (Extract) only
For full text:-Visit the Source
= = = = = = = =
ing collaboratively with all stakeholders to maximize the impact of these reforms across both human and animal health,” stated Sandip Agrawal, Director Finance and Administration, Boehringer Ingelheim India.
He further adds, “A rationalized tax framework directly supports our endeavor to ensure that patients, especially those managing chronic conditions, can benefit from the reduced tax burden on medicines.” Boehringer Ingelheim India is already recalibrating its pricing structures to immediately reflect the revised GST rates and is engaging with healthcare professionals, distributors, and retailers to ensure the changes are implemented swiftly and transparently. The company believes that such reforms lay the foundation for a more equitab
= = = = = = = =
Plain text (Extract) only
For full text:-Visit the Source
= = = = = = = =